ALZAMEND NEURO INC (ALZN:NASDAQ)
$1.31 -0.03 (-2.2388%)
Analysed ALZAMEND NEURO INC (ALZN:NASDAQ) News Sources
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
19-11-2025
yahoo.com
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
19-11-2025
yahoo.com
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth?
20-11-2025
yahoo.com
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
26-01-2026
yahoo.com
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
16-03-2026
yahoo.com
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
26-03-2026
yahoo.com
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
07-04-2026
yahoo.com
What is the current price of ALZAMEND NEURO INC (ALZN:NASDAQ)?
The current price of ALZAMEND NEURO INC (ALZN:NASDAQ) is $1.31.
ALZAMEND NEURO INC (ALZN:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALZAMEND NEURO INC (ALZN:NASDAQ) since the previous trading day is $-0.03.
ALZAMEND NEURO INC (ALZN:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALZAMEND NEURO INC (ALZN:NASDAQ) since the previous trading day is -2.2388%.
What is the most recent average sentiment score for ALZAMEND NEURO INC (ALZN:NASDAQ)?
The most recent average sentiment score for ALZAMEND NEURO INC (ALZN:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for ALZAMEND NEURO INC (ALZN:NASDAQ)?
The most recent sentiment for ALZAMEND NEURO INC (ALZN:NASDAQ) is .
SEC-8K** Filing Available For ALZAMEND NEURO INC (ALZN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.